Durham-based Humacyte, founded by three female scientists in 2004, has received marketing approval from the U.S. Food and ...

Phlebotomy remains the mainstay of treatment in HH; however erythrocytapheresis and novel chelators along with phlebotomy may become the treatment options in the future. The target SF levels ...

Oncurie secures STTR grant to advance targeted treatment for ovarian cancer Oncurie Inc., an RTP company specializing in radiopharmaceuticals and radioisotope chelators for cancer diagnosis and ...